Skip to main content

Table 1 Clinical studies of MS-275 (SNDX-275)

From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Phase Other agent Disease (pt. No.) Schedule Recommended dose Reference
I   Relapsed or refractory AML (39). Once weekly for 4 weeks of a 6 week cycle 8 mg/m2 [92]
I   Refractory solid tumors and lymphoid(22) Once weekly for 4 weeks of a 6 week cycle 6 mg/m2 [90]
I   Refractory solid tumors and lymphoid(27) Once weekly for 3 weeks of a 4 week cycle or once every other week. 4 mg/m2 [91]
I   Refractory solid tumors and lymphoid Once every 2 week of 6 week cycle. 10 mg/m2 [89]